Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary View
Jan 13, 2022
SOUTH PLAINFIELD, N.J. , Jan. 13, 2022 /PRNewswire/ --  PTC Therapeutics, Inc.  (NASDAQ: PTCT) today announced that on Jan. 7, 2022 , the company approved non-statutory stock options to purchase an aggregate of 18,255 shares of its common stock and 10,675 restricted stock units ("RSUs"), each
Additional Formats
Jan 13, 2022
- One-year fellowship provides diverse work experiences across PTC's business areas - SOUTH PLAINFIELD, N.J. , Jan. 13, 2022 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the launch of the company's 2022 Talent Pipeline Program, a one-year, global initiative designed to
Additional Formats
Jan 10, 2022
- $536 million unaudited 2021 total revenue representing impressive 41% year-over-year growth - - $700 - 750 million 2022 total revenue guidance - - Results are expected in four registration-directed trials this year - - Three additional registration-directed clinical trials expected to initiate in
Additional Formats
Jan 04, 2022
- Additional application submitted to ANVISA for a new indication to treat familial partial lipodystrophy - SOUTH PLAINFIELD, N.J. , Jan. 4, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Waylivra™ (volanesorsen) has successfully received Category 1 classification
Additional Formats
Jan 03, 2022
SOUTH PLAINFIELD, N.J. , Jan. 3, 2022 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the 40 th Annual J.P. Morgan Virtual Healthcare Conference on Monday, Jan. 10 , at 7:30 a.m. EST .
Additional Formats
Dec 20, 2021
-- Results published in Nature Communications -- -- Description of novel splicing mechanism causing inhibition of HTT gene expression -- SOUTH PLAINFIELD, N.J. , Dec. 20, 2021 /PRNewswire/ -- PTC Therapeutics , Inc. (NASDAQ: PTCT) today announced the Nature Communications publication characterizing
Additional Formats
Dec 06, 2021
SOUTH PLAINFIELD, N.J. , Dec. 6, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Evrysdi ® (risdiplam) has received multiple awards that recognize it as one of the most innovative therapies of 2021 and for its life-saving impact.
Additional Formats
Dec 02, 2021
SOUTH PLAINFIELD, N.J. , Dec. 2, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Nov. 29, 2021 , the company approved non-statutory stock options to purchase an aggregate of 83,750 shares of its common stock and 21,550 restricted stock units ("RSUs"), each
Additional Formats
Nov 16, 2021
SOUTH PLAINFIELD, N.J. , Nov. 16, 2021 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the 4th Annual Evercore ISI HealthCONx Conference on Tuesday, Nov. 30 at 8:25 a.m. ET . The presentation will be webcast live on the
Additional Formats
Oct 28, 2021
- Total quarterly revenue of $139 million; 17% increase over third quarter 2020 - - Raises 2021 DMD franchise revenue guidance to $400-$420M from $370-$390M - - Continues to advance robust clinical pipeline by initiating a fifth registration-directed trial, APHENITY Phase 3 trial of PTC923 in
Additional Formats